| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Ferroptosis inducer-9 (Compound 12) inhibited microtubule polymerization (IC50 = 550 nM) and inhibited the growth of MCF-7 cells (IC50 = 14 nM)[1]. Ferroptosis inducer-9 (0.3-1 μM) caused complete growth arrest of H2BC11-moxGFP/sTagRFP-TUBA1B-labeled MDA-MB-231 cells and caused significant changes in the morphology of the nucleus and cytoskeleton[1]. Ferroptosis inducer-9 (72 h) inhibited the growth of SW620, SW480, HCT116, HepG2 and CC-2509f cells, with IC50 values of 0.633 μM, 0.0654 μM, 0.389 μM, 107.3 μM and 52.9 μM, respectively[1]. Ferroptosis inducer-9 can downregulate the expression of ferroptosis inhibitors (SLC7A11, SLC3A2, SLC11A2, NRF2, NCOA4, KEAP1, GPX4, FTL, FTH1) in HCT116 cells and upregulate the expression of ferroptosis promoters (PTGS2, NOX1, COX2, COX4, ACSL4) [1]. Ferroptosis inducer-9 can reduce the concentrations of GSH and SOD, reduce the concentrations of NADP+ and NADPH, and increase the levels of LPO, MDA and Fe(II) and GSSG [1].
|
|---|---|
| ln Vivo |
Ferroptosis inducer-9 (compound 12) (25 mg/kg, intraperitoneal injection, every 2 days for 30 days) showed significant antitumor activity in nude mice with proposed HCT116 colorectal cancer xenograft tumors [1].
|
| Animal Protocol |
Animal/Disease Models: HCT116 colorectal cancer cells (1×108 cells/mL in logarithmic growth phase) were subcutaneously implanted into the flanks of 10-week-old male BALB/C mice[1]
Doses: 25 mg/kg Route of Administration: intraperitoneal injection, once every 2 days for 30 days Experimental Results: Achieved tumor growth inhibition. Reduced the Ki67 expression. |
| References |
| Molecular Formula |
C21H18N2O5S
|
|---|---|
| Molecular Weight |
410.44
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4364 mL | 12.1820 mL | 24.3641 mL | |
| 5 mM | 0.4873 mL | 2.4364 mL | 4.8728 mL | |
| 10 mM | 0.2436 mL | 1.2182 mL | 2.4364 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
